Subscribe to RSS

DOI: 10.1055/a-1608-1138
Inadequate Timing Limits the Benefit of Antenatal Corticosteroids on Neonatal Outcome: Retrospective Analysis of a High-Risk Cohort of Preterm Infants in a Tertiary Center in Germany
Schlechtes Timing reduziert den Nutzen von antenatalen Kortikosteroiden für das neonatale Outcome: eine retrospektive Analyse einer Hochrisikogruppe von Frühgeborenen in einem deutschen Perinatalzentrum Level 1
Abstract
Introduction A common problem in the treatment of threatened preterm birth is the timing and the unrestricted use of antenatal corticosteroids (ACS). This study was performed to evaluate the independent effects of the distinct timing of antenatal corticosteroids on neonatal outcome parameters in a cohort of very low (VLBW; 1000 – 1500 g) and extreme low birth weight infants (ELBW; < 1000 g). We hypothesize that a prolonged ACS-to-delivery interval leads to an increase in respiratory complications.
Materials and Methods Main data source was the prospectively collected single center data for the German nosocomial infection surveillance system (KISS) between 2015 and 2018. Multivariate regression analysis was performed to determine independent effects of the ACS-to-delivery interval on the need for ventilation, surfactant or the occurrence of bronchopulmonary dysplasia, neonatal sepsis or necrotizing enterocolitis. Subgroup analysis was performed for ELBW and VLBW neonates.
Results A total of 239 neonates were included. We demonstrate a significantly increased risk of respiratory distress characterized by the need for ventilation (OR 1.045; CI 1.011 – 1.080) and surfactant administration (OR 1.050, CI 1.018 – 1.083) depending on the ACS-to-delivery interval irrespective of other confounders. Every additional day between ACS and delivery increased the risk for ventilation by 4.5% and for surfactant administration by 5%. Subgroup analysis revealed significant differences of respiratory complications in VLBW infants.
Conclusions Our data strongly support the deliberate use and timing of antenatal corticosteroids in pregnancies with threatened preterm birth versus a liberal strategy. When given more than 7 days before birth, each day between application and delivery increases is relevant concerning major effects on the infant. Especially VLBW preterm neonates benefit from optimal timing.
Zusammenfassung
Introduction Die uneingeschränkte Gabe von antenatalen Kortikosteroiden (ACS) und der Zeitpunkt dieser Gabe stellen ein verbreitetes Problem in der Behandlung drohender Frühgeburten dar. Ziel dieser Studie war es, die unabhängige Wirkung pränataler Gaben von Kortikosteroiden zu unterschiedlichen Zeitpunkten auf die neonatalen Outcome-Parameter in einer Gruppe von Neugeborenen mit sehr niedrigem (very-low-birthweight, VLBW; 1000 – 1500 g) bzw. extrem niedrigem Geburtsgewicht (extremely-low-birthweight, ELBW; < 1000 g) zu evaluieren. Wir stellten die Hypothese auf, dass ein langer Intervall zwischen ACS-Gabe und Geburt zu einem Ansteig der Atemwegskomplikationen führt.
Material und Methoden Die Hauptdatenquelle waren prospektive monozentrische Daten, die für das deutsche Überwachungssystem für nosokomiale Infektionen (KISS) in einem einzigen Zentrum zwischen 2015 und 2018 gesammelt wurden. Es wurde eine multivariate Regressionsanalyse durchgeführt, um die unabhängige Wirkung des Intervalls zwischen ACS-Gabe und Geburt auf den Bedarf nach künstlicher Beatmung bzw. einer Surfactant-Therapie sowie das Auftreten einer bronchopulmonalen Dysplasie, einer neonatalen Sepsis oder einer nekrotisierenden Enterokolitis zu bestimmen. Es wurden Untergruppenanalysen für die Gruppen der ELBW- und der VLBW-Neugeborenen durchgeführt.
Ergebnisse Insgesamt wurden 239 Neugeborenen in die Studie aufgenommen. Wir fanden ein signifikant höheres Risiko für ein Atemnotsyndrom, das durch die Notwendigkeit einer mechanischen Beatmung (OR 1,045; KI 1,011 – 1,080) bzw. einer Surfactant-Gabe (OR 1,050, KI 1,018 – 1,083) gekennzeichnet war. Ungeachtet anderer Störfaktoren hing das Risiko von der Dauer des Intervalls zwischen ACS-Gabe und Geburt ab. Jeder zusätzliche Tag zwischen ACS-Gabe und Geburt erhöhte das Risiko für eine mechanische Beatmung um 4,5% und für eine Surfactant-Therapie um 5%. Die Untergruppenanalyse zeigte signifikante Unterschiede in den Atemwegskomplikationen bei VLBW-Neugeborenen.
Schlussfolgerungen Unsere Daten unterstreichen die Bedeutung, die ein bewusster Einsatz und das richtigen Timing von ACS-Gaben bei Schwangerschaften mit drohender Frühgeburt anstatt einer liberalen Strategie hat. Wenn die ACS-Gabe mehr als 7 Tage vor der Geburt erfolgt, kann jeder zusätzliche Tag zwischen ACS-Gabe und Geburt wichtige Auswirkungen auf das Neugeborene haben. Besonders VLBW-Frühgeborene profitieren von einem optimalen Timing.
Key words
antenatal corticosteroids - preterm birth - VLWB - perinatal outcome - respiratory distress syndromeSchlüsselwörter
antenatale Kortikosteroide - Frühgeburt - VLWB - perinatales Outcome - Atemnotsyndrom des FrühgeborenenPublication History
Received: 03 May 2021
Accepted after revision: 22 August 2021
Article published online:
03 March 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Stavropoulou D, Hentschel R. [Antenatal Steroid Therapy in Threatened Premature Birth – State of the Art]. Z Geburtshilfe Neonatol 2017; 221: 265-271
- 2 Schleussner E. The prevention, diagnosis and treatment of premature labor. Dtsch Arztebl Int 2013; 110: 227-235 quiz 236
- 3 Roberts D, Brown J, Medley N. et al. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2017; (03) CD004454
- 4 Jobe AH, Soll RF. Choice and dose of corticosteroid for antenatal treatments. Am J Obstet Gynecol 2004; 190: 878-881
- 5 Crowley PA. Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol 1995; 173: 322-335
- 6 Travers CP, Carlo WA, McDonald SA. et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Mortality and pulmonary outcomes of extremely preterm infants exposed to antenatal corticosteroids. Am J Obstet Gynecol 2018; 218: 130.e1-130.e13
- 7 Ballard PL, Ballard RA. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obstet Gynecol 1995; 173: 254-262
- 8 Bolt RJ, van Weissenbruch MM, Lafeber HN. et al. Glucocorticoids and lung development in the fetus and preterm infant. Pediatr Pulmonol 2001; 32: 76-91
- 9 [Anonym] Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. JAMA 1995; 273: 413-418
- 10 Lau HCQ, Tung JSZ, Wong TTC. et al. Timing of antenatal steroids exposure and its effects on neonates. Arch Gynecol Obstet 2017; 296: 1091-1096
- 11 Crowther CA, McKinlay CJ, Middleton P. et al. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database Syst Rev 2015; 2015 (07) CD003935
- 12 Vidaeff AC, Ramin SM, Gilstrap 3rd LC. et al. Characterization of corticosteroid redosing in an in vitro cell line model. Am J Obstet Gynecol 2004; 191: 1403-1408
- 13 Vermillion ST, Soper DE, Newman RB. Is betamethasone effective longer than 7 days after treatment?. Obstet Gynecol 2001; 97: 491-493
- 14 Ring AM, Garland JS, Stafeil BR. et al. The effect of a prolonged time interval between antenatal corticosteroid administration and delivery on outcomes in preterm neonates: a cohort study. Am J Obstet Gynecol 2007; 196: 457.e1-e6
- 15 Sehdev HM, Abbasi S, Robertson P. et al. The effects of the time interval from antenatal corticosteroid exposure to delivery on neonatal outcome of very low birth weight infants. Am J Obstet Gynecol 2004; 191: 1409-1413
- 16 Peaceman AM, Bajaj K, Kumar P. et al. The interval between a single course of antenatal steroids and delivery and its association with neonatal outcomes. Am J Obstet Gynecol 2005; 193: 1165-1169
- 17 van Baaren GJ, Vis JY, Wilms FF. et al. Predictive value of cervical length measurement and fibronectin testing in threatened preterm labor. Obstet Gynecol 2014; 123: 1185-1192
- 18 McPheeters ML, Miller WC, Hartmann KE. et al. The epidemiology of threatened preterm labor: a prospective cohort study. Am J Obstet Gynecol 2005; 192: 1325-1329 discussion 1329–1330
- 19 Levin HI, Ananth CV, Benjamin-Boamah C. et al. Clinical indication and timing of antenatal corticosteroid administration at a single centre. BJOG 2016; 123: 409-414
- 20 Razaz N, Skoll A, Fahey J. et al. Trends in optimal, suboptimal, and questionably appropriate receipt of antenatal corticosteroid prophylaxis. Obstet Gynecol 2015; 125: 288-296
- 21 Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatrics 2013; 13: 59
- 22 Walsh MC, Yao Q, Gettner P. et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics 2004; 114: 1305-1311
- 23 Leistner R, Piening B, Gastmeier P. et al. Nosocomial Infections in Very Low Birthweight Infants in Germany: Current Data from the National Surveillance System NEO-KISS. Klin Padiatr 2013; 225: 75-80
- 24 Sarquis AL, Miyaki M, Cat MN. [The use of CRIB score for predicting neonatal mortality risk]. J Pediatr (Rio J) 2002; 78: 225-229
- 25 Peduzzi P, Concato J, Kemper E. et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49: 1373-1379
- 26 Hušková M, Meintanis SG. Omnibus tests for the error distribution in the linear regression model. Statistics 2007; 41: 363-376
- 27 Carreno CA, Refuerzo JS, Holland MG. et al. The Frequency of Prior Antenatal Corticosteroid Therapy in Late Preterm Birth Pregnancies. Am J Perinatol 2011; 28: 767-772
- 28 Boßung V, Rody A. Eine Frage des Timings: Retrospektive 10-Jahres-Analyse zur RDS-Prophylaxe bei Frühgeburten vor 34 + 0 SSW. Geburtshilfe Frauenheilkd 2018; 78: 238
- 29 Langhammer K, Roth B, Kribs A. et al. Treatment and outcome data of very low birth weight infants treated with less invasive surfactant administration in comparison to intubation and mechanical ventilation in the clinical setting of a cross-sectional observational multicenter study. Eur J Pediatr 2018; 177: 1207-1217
- 30 Hartel C, Paul P, Hanke K. et al. Less invasive surfactant administration and complications of preterm birth. Sci Rep 2018; 8: 8333
- 31 Deshmukh M, Patole S. Antenatal corticosteroids for neonates born before 25 Weeks-A systematic review and meta-analysis. PLoS One 2017; 12: e0176090
- 32 Bernstein IM, Horbar JD, Badger GJ. et al. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. Am J Obstet Gynecol 2000; 182: 198-206
- 33 Torrance HL, Derks JB, Scherjon SA. et al. Is antenatal steroid treatment effective in preterm IUGR fetuses?. Acta Obstet Gynecol Scand 2009; 88: 1068-1073
- 34 Morrison JL, Botting KJ, Soo PS. et al. Antenatal steroids and the IUGR fetus: are exposure and physiological effects on the lung and cardiovascular system the same as in normally grown fetuses?. J Pregnancy 2012; 2012: 839656
- 35 Onland W, de Laat MW, Mol BW. et al. Effects of antenatal corticosteroids given prior to 26 weeksʼ gestation: a systematic review of randomized controlled trials. Am J Perinatol 2011; 28: 33-44